Text Size

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Avid Radiopharmaceuticals
ClinicalTrials.gov Identifier:
NCT00857415
First received: March 5, 2009
Last updated: May 17, 2012
Last verified: May 2012
History of Changes
Results First Received: April 6, 2012  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Diagnostic
Condition: Alzheimer's Disease
Intervention: Drug: florbetapir F 18

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Autopsy Cohort End-of-life subjects consenting to brain donation at autopsy. Subjects received a single intravenous injection of 370 MBq florbetapir followed by a 10-minute PET scan 50 minutes post-injection.
Specificity Cohort Younger healthy controls presumed to be devoid of beta-amyloid plaques. Subjects received a single intravenous injection of 370 MBq florbetapir followed by a 10-minute PET scan 50 minutes post-injection.

Participant Flow:   Overall Study
    Autopsy Cohort     Specificity Cohort  
STARTED     152     74  
Deceased Within One Year of AV-45 Scan     37     0 [1]
COMPLETED     35     74  
NOT COMPLETED     117     0  
Image acquisition failure                 2                 0  
Invalid image or not imaged                 3                 0  
Subject still living at end of study                 110                 0  
Deceased with no autopsy                 2                 0  
[1] Subjects in the specificity cohort were not followed to autopsy



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Autopsy Cohort End-of-life subjects consenting to brain donation at autopsy. Subjects received a single intravenous injection of 370 MBq florbetapir followed by a 10-minute PET scan 50 minutes post-injection.
Specificity Cohort Younger healthy controls presumed to be devoid of beta-amyloid plaques. Subjects received a single intravenous injection of 370 MBq florbetapir followed by a 10-minute PET scan 50 minutes post-injection.
Total Total of all reporting groups

Baseline Measures
    Autopsy Cohort     Specificity Cohort     Total  
Number of Participants  
[units: participants]
 		  152     74     226  
Age  
[units: years]
Mean ± Standard Deviation 		  78.1  ± 13.35     26.6  ± 6.50     61.3  ± 26.84  
Gender  
[units: participants]
 		     
Female     81     26     107  
Male     71     48     119  
Region of Enrollment  
[units: participants]
 		     
United States     152     74     226  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Correlation of Florbetapir-PET Image and Amyloid Plaque Density   [ Time Frame: at autopsy up to 12 months post-scan ]
  Show Outcome Measure 1

2.  Primary:   Specificity Analysis   [ Time Frame: 50-60 min after injection ]
  Show Outcome Measure 2

3.  Secondary:   Regional Correlation Analysis   [ Time Frame: at autopsy up to 12 months post-scan ]
  Hide Outcome Measure 3

Measure Type Secondary
Measure Title Regional Correlation Analysis
Measure Description Spearman's rank order correlation of median visual read of the florbetapir-PET image vs. amyloid plaque density assessed post-mortem by quantitative IHC of six individual brain regions (precuneus, parietal cortex, frontal cortex, temporal cortex, posterior cingulate, anterior cingulate). Spearman's rank order correlation ranges from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive correlation.
Time Frame at autopsy up to 12 months post-scan  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All subjects with a valid image who came to autopsy within 1 year of scan, minus 6 subjects who served as front-runners

Reporting Groups
  Description
Autopsy Cohort End-of-life subjects consenting to brain donation at autopsy

Measured Values
    Autopsy Cohort  
Number of Participants Analyzed  
[units: participants]
 		  29  
Regional Correlation Analysis  
[units: Correlation coefficient]
Number ( 95% Confidence Interval ) 		 
Precuneus     0.75  
  ( 0.53 to 0.88 )  
Parietal cortex     0.77  
  ( 0.56 to 0.88 )  
Frontal cortex     0.69  
  ( 0.44 to 0.84 )  
Temporal cortex     0.68  
  ( 0.42 to 0.84 )  
Posterior cingulate     0.70  
  ( 0.44 to 0.85 )  
Anterior cingulate     0.74  
  ( 0.51 to 0.87 )  

No statistical analysis provided for Regional Correlation Analysis




  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Chief Medical Officer
Organization: Avid Radiopharmaceuticals
phone: 215-298-0700
e-mail: clinicaloperations@avidrp.com


Publications of Results:


Responsible Party: Avid Radiopharmaceuticals
ClinicalTrials.gov Identifier: NCT00857415     History of Changes
Other Study ID Numbers: 18F-AV-45-A07
Study First Received: March 5, 2009
Results First Received: April 6, 2012
Last Updated: May 17, 2012
Health Authority: United States: Food and Drug Administration